Compare International Business Machines Corp (IBM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
International Business Machines Corp vs State Street SPDR S&P Biotech ETF — how do they compare? International Business Machines Corp trades at $227.08 (market cap $213.50B), while State Street SPDR S&P Biotech ETF trades at $153.99 (market cap $10.11B). The key difference: International Business Machines Corp is far larger — about 21.1× State Street SPDR S&P Biotech ETF's market cap, and International Business Machines Corp pays a 2.98% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold International Business Machines Corp for 88 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| IBM | XBI | |
|---|---|---|
Market Cap | $213.50B | $10.11B |
Volume | 8,908,687 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $329.23 | $169.55 |
52-Week Low | $205.77 | $104.99 |
Typical Hold Time | 88 Days | 38 Days |
Enterprise Value | $270.64B | — |
Dividend Yield | 2.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBM stock trades at $227.44, up 3.14% with recent momentum driven by positive sentiment in the consulting sector following Accenture's strong earnings. The company shows solid fundamentals with 2025 revenue of $67.54B and net income of $10.59B, though technical indicators suggest bearish momentum with the stock trading near resistance at $230. Recent developments include the self-hosted deployment option for IBM Bob AI platform, enhancing enterprise AI sovereignty capabilities.
IBM presents a mixed investment case with strong profitability metrics (15.52% net margin, 34.62% ROE) and analyst consensus price target of $255.50 offering 12% upside potential. However, bearish technical signals, recent earnings miss in Q2 2026, and increased investing cash outflows (-$10.3B in 2025) present near-term headwinds. The stock's valuation at 20.13 P/E appears reasonable given the company's hybrid cloud and AI consulting growth trajectory.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
